ArchiMed is a management entity listed as an executive officer on 2 SEC Form D filings by 2 issuers in Feb 2022: MPI-COI-CARSO SLP (Lyon, France (as filed: I0) — pooled investment fund — 2022; $12.6M reported sold to 3 investors) and MPI-COI-SUAN SLP (Lyon, France (as filed: I0) — pooled investment fund — 2022; $11.9M reported sold to 2 investors).
What this means 2 separate companies raised money with this person listed as executive officer. Across those companies the filings report $24.4M sold in total.
Listed alongside MED Platform II GP (2 shared filings, management entity).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around ArchiMed. Each name links to their own page.
All 2 issuers belong to the sponsor group Mpi Coi (2 issuers, $24.4M reported sold, 2022).
What this means A sponsor group is one team that sets up a new company for each deal. Mpi Coi has 2 companies on file and $24.4M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for ArchiMed and found 4 differences, 2 worth asking the sponsor about: Form D filed 99 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.